Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Classical hematology 1

Conditions

Thrombosis 1Hematologic Neoplasms 1Catheter-Related Infections 1Bacteremia 1

Interventions

Cyclophosphamide 122Cytarabine 112fludarabine 91fludarabine phosphate 80Rituximab 75Azacitidine 75venetoclax 55Methotrexate 52Filgrastim 48Whole-Body Irradiation 45Busulfan 45Tacrolimus 35Etoposide 35Mycophenolic Acid 34Lenalidomide 32Imatinib Mesylate 32Antilymphocyte Serum 32Granulocyte Colony-Stimulating Factor 31Decitabine 31Peripheral Blood Stem Cell Transplantation 29Dexamethasone 29Cyclosporine 29Vincristine 26Melphalan 26Clofarabine 25Alemtuzumab 25Mitoxantrone 24Stem Cell Transplantation 22Radiotherapy 22Dasatinib 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Heparin × Other hematologic neoplasm × Clear all
NCT01820962 2013-03-29

Concentrated Citrate Locking to Reduce the Incidence of CVC-related Complications in Hematological Patients

Maastricht University Medical Center

Phase 3 Terminated
212 enrolled
Other hematologic neoplasm

Thrombosis, Bacteremia, Hematologic Neoplasms, Catheter-Related Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡